Have any questions?
+44 1234 567 890
Impulse Dynamics
Sustainable and strategic product positioning in key Latin American markets (BRA, COL and MEX).
In July 2022, the new Brazilian guidelines for the diagnosis and treatment of myocarditis were published.
These guidelines take into account the current scientific evidence and now recommend the use of endomyocardial biopsies (EMB) according to a well-defined scheme (yellow marker).
i²medi Comercial Medical Ltda. in Brazil, has been working on behalf of the world's leading laboratory for differential EMB diagnosis, the IKDT (INSTITUT KARDIALE DIAGNOSTIK und THERAPIE GMBH) in Berlin, on the business development of EMBs in Brazil for over 4 years.
The inclusion of endomyocardial biopsies (EMBs) in the treatment pathway is a significant milestone in providing patients with individualized therapy to improve their clinical prognosis in the future.